FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977883224> ?p ?o ?g. }

• W2977883224 endingPage "v718" @default.
• W2977883224 startingPage "v718" @default.
• W2977883224 abstract "Abstract Background Clinical trials, focusing on selected pts, may have underestimated toxicities in cases with advanced age and co-morbidities, that are common in RW practice. Furthermore, clinical trials do not provide extended F/U. Thus, we assessed acute and long-term SCEs after adjuvant T in a large/unselected BC pt population. Methods Using healthcare administrative database, ie clinical discharge records and drug prescriptions of the Lombardy region (Italy), we selected pts newly diagnosed with early BC between 01/2008 and 12/2011 and monitored until 12/2016. Pts treated with T were 1:2 matched with pts treated with chemotherapy only for age, date of treatment, and cardiovascular risk factors. SCEs included heart failure and cardiomyopathy based on ICD9-CM codes. The cumulative risk of SCEs was estimated using the Kaplan-Meier method; independent predictors were assessed by the Cox regression model. Results Of a cohort of 34,218 pts with incident BC, 2,809 pts treated with T were matched to 5,618 pts treated with chemotherapy only. One SCE during F/U was experienced in 52 (1.8%) of T-users and 88 (0.26%) of non-T users. No cardiac death occurred. The 1-year cumulative risk of SCEs was 0.96%, with 1/4 of SCEs occurring within the first 6 months, in T-users, and 0.16% in non T-users. However, the T-user excess risk disappeared after 1 year of T. Thus, the hazard ratio [HR] was 9.96 (95%CI 3-78-26.2) during the first year, and 1.41 (95%CI 0.99-2.02) during the entire F/U period. HR was higher in the elderly, age>70 years, 8.77 (95%CI 5.25-14.64), and in pts with at least one pre-existing CRFs 2.32 (95%CI 1.68-3.22). Conclusions In RW practice, SCEs during/after T are infrequent, early and self-limiting. Based on the timeline of SCEs, it might be unnecessary to monitor cardiac toxicity beyond the period of T treatment. Besides, to reduce the excess of cardiac risk of the first year, strategies including shortening T exposure or increasing the number of check-ups in asymptomatic pts should be accompanied by the development of biomarker(s) able to identify pts at risk before/immediately after T initiation. Legal entity responsible for the study Serena Di Cosimo. Funding Associazione Italiana per la Ricerca sul Cancro (AIRC). Disclosure S. Di Cosimo: Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Teva; Advisory / Consultancy: EpiOnpharma; Advisory / Consultancy: Bayer; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: GSK; Travel / Accommodation / Expenses: Celgene. All other authors have declared no conflicts of interest." @default.
• W2977883224 created "2019-10-10" @default.
• W2977883224 creator A5001910485 @default.
• W2977883224 creator A5022257735 @default.
• W2977883224 creator A5022938359 @default.
• W2977883224 creator A5033825608 @default.
• W2977883224 creator A5035544605 @default.
• W2977883224 creator A5045075334 @default.
• W2977883224 creator A5047822022 @default.
• W2977883224 creator A5052679679 @default.
• W2977883224 date "2019-10-01" @default.
• W2977883224 modified "2023-09-23" @default.
• W2977883224 title "Long term follow-up (F/U) report of symptomatic cardiac events (SCEs) in 2,809 breast cancer (BC) patients (pts) treated with adjuvant trastuzumab (T) in real world (RW) practice" @default.
• W2977883224 doi "https://doi.org/10.1093/annonc/mdz265" @default.
• W2977883224 hasPublicationYear "2019" @default.
• W2977883224 type Work @default.
• W2977883224 sameAs 2977883224 @default.
• W2977883224 citedByCount "0" @default.
• W2977883224 crossrefType "journal-article" @default.
• W2977883224 hasAuthorship W2977883224A5001910485 @default.
• W2977883224 hasAuthorship W2977883224A5022257735 @default.
• W2977883224 hasAuthorship W2977883224A5022938359 @default.
• W2977883224 hasAuthorship W2977883224A5033825608 @default.
• W2977883224 hasAuthorship W2977883224A5035544605 @default.
• W2977883224 hasAuthorship W2977883224A5045075334 @default.
• W2977883224 hasAuthorship W2977883224A5047822022 @default.
• W2977883224 hasAuthorship W2977883224A5052679679 @default.
• W2977883224 hasBestOaLocation W29778832241 @default.
• W2977883224 hasConcept C121332964 @default.
• W2977883224 hasConcept C121608353 @default.
• W2977883224 hasConcept C126322002 @default.
• W2977883224 hasConcept C143998085 @default.
• W2977883224 hasConcept C2777863537 @default.
• W2977883224 hasConcept C2779786085 @default.
• W2977883224 hasConcept C2779974597 @default.
• W2977883224 hasConcept C3018227240 @default.
• W2977883224 hasConcept C512399662 @default.
• W2977883224 hasConcept C530470458 @default.
• W2977883224 hasConcept C61797465 @default.
• W2977883224 hasConcept C62520636 @default.
• W2977883224 hasConcept C71924100 @default.
• W2977883224 hasConceptScore W2977883224C121332964 @default.
• W2977883224 hasConceptScore W2977883224C121608353 @default.
• W2977883224 hasConceptScore W2977883224C126322002 @default.
• W2977883224 hasConceptScore W2977883224C143998085 @default.
• W2977883224 hasConceptScore W2977883224C2777863537 @default.
• W2977883224 hasConceptScore W2977883224C2779786085 @default.
• W2977883224 hasConceptScore W2977883224C2779974597 @default.
• W2977883224 hasConceptScore W2977883224C3018227240 @default.
• W2977883224 hasConceptScore W2977883224C512399662 @default.
• W2977883224 hasConceptScore W2977883224C530470458 @default.
• W2977883224 hasConceptScore W2977883224C61797465 @default.
• W2977883224 hasConceptScore W2977883224C62520636 @default.
• W2977883224 hasConceptScore W2977883224C71924100 @default.
• W2977883224 hasLocation W29778832241 @default.
• W2977883224 hasOpenAccess W2977883224 @default.
• W2977883224 hasPrimaryLocation W29778832241 @default.
• W2977883224 hasRelatedWork W1722328147 @default.
• W2977883224 hasRelatedWork W2032502319 @default.
• W2977883224 hasRelatedWork W2066747782 @default.
• W2977883224 hasRelatedWork W2098775844 @default.
• W2977883224 hasRelatedWork W2626167847 @default.
• W2977883224 hasRelatedWork W2934076975 @default.
• W2977883224 hasRelatedWork W4361935173 @default.
• W2977883224 hasRelatedWork W4361935318 @default.
• W2977883224 hasRelatedWork W4361969539 @default.
• W2977883224 hasRelatedWork W2342209702 @default.
• W2977883224 hasVolume "30" @default.
• W2977883224 isParatext "false" @default.
• W2977883224 isRetracted "false" @default.
• W2977883224 magId "2977883224" @default.
• W2977883224 workType "article" @default.